This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
How Much Upside is Left in Dynavax Technologies (DVAX)? Wall Street Analysts Think 135.98%
by Zacks Equity Research
The mean of analysts' price targets for Dynavax Technologies (DVAX) points to a 136% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Dynavax Technologies (DVAX) Tops Q2 Earnings Estimates
by Zacks Equity Research
Dynavax Technologies (DVAX) delivered earnings and revenue surprises of 33.33% and 4.06%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for July 9th
by Zacks Equity Research
BMWYY, DXC and DVAX have been added to the Zacks Rank #5 (Strong Sell) List on July 9, 2024.
Dynavax Technologies (DVAX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Dynavax Technologies (DVAX) delivered earnings and revenue surprises of -40% and 2.29%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Myriad Genetics (MYGN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Myriad (MYGN) delivered earnings and revenue surprises of 90.91% and 4.55%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Dynavax Technologies (DVAX) Reports Break-Even Earnings for Q4
by Zacks Equity Research
Dynavax Technologies (DVAX) delivered earnings and revenue surprises of 100% and 1%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Pacira (PCRX) Preliminary '23 Revenues Solid, Exparel Strong
by Zacks Equity Research
Pacira (PCRX) posts preliminary revenues for the fourth quarter and full year 2023.
Axsome (AXSM) Stock Rises on Stellar Q4 Preliminary Results
by Zacks Equity Research
Axsome (AXSM) issues encouraging preliminary results for the fourth quarter and full-year 2023. The company also provides regulatory updates on its pipeline candidates. Shares rise.
Dynavax Technologies (DVAX) Is a Great Choice for 'Trend' Investors, Here's Why
by Zacks Equity Research
Dynavax Technologies (DVAX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Collegium (COLL) Shares Rise on Financial Outlook for 2024
by Zacks Equity Research
Collegium (COLL) reports financial guidance for full-year 2024 and business updates. Shares of the company rise on the same.
Assertio (ASRT) Shares Fall as Dan Peisert Steps Down as CEO
by Zacks Equity Research
Assertio (ASRT) appoints Heather Mason as its interim CEO as its current CEO, Dan Peisert, steps down from his role. Shares of the company fall on the same.
Voyager (VYGR) Gains on Gene Therapy Deal With Novartis
by Zacks Equity Research
Voyager (VYGR) enters into a capsid license agreement with Novartis for Huntington's disease and spinal muscular atrophy. The infusion of cash will extend the company's cash runway.
C4 Therapeutics (CCCC) Gains 310% in 3 Months: Here's Why
by Zacks Equity Research
C4 Therapeutics (CCCC) shares surge on a licensing deal to develop degrader-antibody conjugates with Merck and positive data from CFT7455 studies.
BEAM Stock Rallies More Than 25% in 3 Months: What Next?
by Zacks Equity Research
BEAM is making good progress with its lead pipeline candidate, BEAM-101, which is being developed for treating sickle cell disease. Also, the recent restructuring efforts are expected to reduce costs.
Roche (RHHBY) to Acquire LumiraDx's Point of Care Technology
by Zacks Equity Research
Roche (RHHBY) is set to acquire LumiraDx's Point of Care technology for $295 million and an additional payment of up to $55 million.
Bayer (BAYRY) Loses 28% in 2023: What to Expect in 2024?
by Zacks Equity Research
Bayer (BAYRY) faced challenges in 2023 as sales declined in the Crop Science division. Pipeline setbacks also weighed on the stock.
Mirum (MIRM) Down on Failure of Mid-Stage Study on Livmarli
by Zacks Equity Research
Mirum (MIRM) faces a setback in its efforts to expand its lead drug Livmarli's label for the indication of biliary atresia in patients who have undergone a Kasai surgery.
Bristol Myers (BMY) Stops Late-Stage Colorectal Cancer Study
by Zacks Equity Research
Bristol Myers (BMY) decides to discontinue the phase III colorectal cancer study as it was unlikely to meet its primary endpoints upon completion.
3 Biotech Stocks Most Wall Street Analysts Are Bullish About
by Ekta Bagri
Here we present three biotech stocks, CRSP, ITCI and DVAX, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2024, backed by strong fundamentals.
Gilead (GILD) Outperforms Industry in 6 Months: What Lies Ahead?
by Zacks Equity Research
Gilead (GILD) gains 3.7% in six months as its oncology portfolio gains traction and its HIV business maintains momentum.
NextCure (NXTC) Down on Shelving Plans to Develop Candidate
by Zacks Equity Research
NextCure (NXTC) plans to focus on developing LNCB74 and stop the development of NC762 to conserve cash. The company's shares decline on the same.
Vertex (VRTX) Hits Record High on Non-Opioid Pain Drug Data
by Zacks Equity Research
Vertex (VRTX) stock hits a 52-week high after announcing encouraging data from a phase II study on non-opioid pain medicine, VX-548, for treating painful diabetic peripheral neuropathy.
Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Aquestive Therapeutics (AQST) and Dynavax Technologies (DVAX) have performed compared to their sector so far this year.
Regeneron (REGN) Posts Positive Data on Blood Cancer Candidate
by Zacks Equity Research
Regeneron's (REGN) multiple myeloma candidate demonstrates strong rates and depth of response in pre-treated patients.
Novartis (NVS) Gets FDA Nod for Rare Blood Disorder Drug
by Zacks Equity Research
Novartis (NVS) obtains FDA approval for Fabhalta, the first oral monotherapy for treating adults with PNH.